Research programme: CNS disorders therapeutics - RexahnAlternative Names: RX-10,000
Latest Information Update: 06 May 2010
At a glance
- Originator Revaax Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anxiety disorders; Cognition disorders; Major depressive disorder; Neurological disorders; Neuropathic pain
Most Recent Events
- 19 May 2005 Preclinical trials in Cognition disorders in USA (unspecified route)
- 19 May 2005 Preclinical trials in Neurological disorders in USA (unspecified route)
- 19 May 2005 Preclinical trials in Depression in USA (unspecified route)